Investment Thesis
Anteris is a pre-revenue orthopedic device company burning $28.7M annually in operations with only $494K in quarterly revenue and no YoY growth, leaving approximately 1.1 years of cash runway. The company exhibits catastrophic operating margins of -4860% and no demonstrated path to profitability, and while the balance sheet remains strong, operational fundamentals are severely deteriorated.
Strengths
- Strong balance sheet with $278.4M stockholders' equity and minimal $18K long-term debt
- Adequate liquidity position with $31.7M cash reserves and exceptional 20.93x current ratio
- Positive cash position provides runway for continued operations and R&D investment
Risks
- Minimal revenue generation at $494K quarterly with zero YoY growth indicates failed commercialization
- Operating cash burn of $28.7M annually with only ~1.1 years of runway at current rate
- Massive operating losses of $24M and net losses of $23M on negligible revenue demonstrate broken unit economics
- Orthopedic device sector requires substantial R&D and regulatory costs with uncertain success probability
- No visible path to profitability or positive operating cash flow based on current operational performance
Key Metrics to Watch
- Quarterly revenue levels and YoY growth rate toward breakeven threshold
- Operating cash flow burn rate and months of remaining cash runway
- Regulatory approval status and product launch timeline for revenue-generating devices
- Gross margin achievement and operating leverage upon revenue inflection
- Working capital changes and stockholders' equity deterioration trajectory
Financial Metrics
Revenue
494.0K
Net Income
-23.0M
EPS (Diluted)
$-0.28
Free Cash Flow
-28.8M
Total Assets
294.7M
Cash
31.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,859.7%
Net Margin
-4,660.7%
ROE
-8.3%
ROA
-7.8%
FCF Margin
-5,833.4%
Balance Sheet & Liquidity
Current Ratio
20.93x
Quick Ratio
20.93x
Debt/Equity
0.00x
Debt/Assets
5.5%
Interest Coverage
-889.15x
Long-term Debt
18.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:57:20.958407 |
Data as of: 2026-03-31 |
Powered by Claude AI